Sequana Medical Beheer

Beheer criteriumcontroles 4/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Ian Crosbie

Algemeen directeur

€440.6k

Totale compensatie

Percentage CEO-salaris	96.5%
Dienstverband CEO	8.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	5.6yrs
Gemiddelde ambtstermijn bestuur	5.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ian Crosbie's beloning veranderd ten opzichte van Sequana Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-€27m
Mar 31 2024	n/a	n/a	-€30m
Dec 31 2023	€441k	€425k	-€33m
Sep 30 2023	n/a	n/a	-€32m
Jun 30 2023	n/a	n/a	-€32m
Mar 31 2023	n/a	n/a	-€32m
Dec 31 2022	€464k	€449k	-€31m
Sep 30 2022	n/a	n/a	-€29m
Jun 30 2022	n/a	n/a	-€27m
Mar 31 2022	n/a	n/a	-€25m
Dec 31 2021	€417k	n/a	-€24m

Compensatie versus markt: Ian 's total compensation ($USD477.43K) is about average for companies of similar size in the Belgian market ($USD432.97K).

Compensatie versus inkomsten: Ian 's compensation has been consistent with company performance over the past year.

CEO

Ian Crosbie

8.8yrs

Tenure

€440,569

Compensatie

Mr. Ian Crosbie is the Chief Executive Officer of Sequana Medical NV since 2016 and serves as its Director since 2019. Mr. Crosbie has been the Chief Executive Officer of Sequana Medical AG since December...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ian Crosbie	CEO & Executive Director	8.8yrs	€440.57k	geen gegevens
Kirsten Van Bockstaele	Chief Financial Officer	no data	€355.98k	geen gegevens
Lies Vanneste	Director of Investor Relations	5.6yrs	geen gegevens	geen gegevens
Martijn Blom	Chief Commercial Officer	no data	geen gegevens	geen gegevens
Oliver Godje	Chief Medical Officer	4.5yrs	geen gegevens	geen gegevens

5.6yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: SEQUA's management team is seasoned and experienced (5.6 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ian Crosbie	CEO & Executive Director	5.8yrs	€440.57k	geen gegevens
Erik Amble	Observer	2.3yrs	geen gegevens	0.045% € 16.4k
Wim Ottevaere	Independent Non-Executive Director	5.8yrs	€52.50k	0.057% € 20.7k
James Udelson	Heart Failure Scientific Advisor	4.1yrs	geen gegevens	geen gegevens
Rudy Dekeyser	Non-Executive Director	no data	geen gegevens	geen gegevens
Maria Costanzo	Scientific Advisor	5.2yrs	geen gegevens	geen gegevens
Pierre Chauvineau	Independent Chairman	5.8yrs	€71.50k	0.019% € 6.9k
Javed Butler	Scientific Advisor	5.2yrs	geen gegevens	geen gegevens
Jeffrey Testani	Scientific Advisor	5.2yrs	geen gegevens	geen gegevens
W.H. Tang	Scientific Advisor	5.2yrs	geen gegevens	geen gegevens
Jackie Fielding	Independent Non-Executive Director	3.2yrs	€49.00k	geen gegevens
G. Felker	Heart Failure Scientific Advisor	4.1yrs	geen gegevens	geen gegevens

5.2yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: SEQUA's board of directors are considered experienced (5.2 years average tenure).

Sequana Medical Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Sequana Medical NV, Annual General Meeting, May 23, 2024

Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director

Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director

High number of new directors

Sequana Medical NV Announces Board Changes

Sequana Medical NV Appoints Doug Kohrs as an Independent Non-Executive Director of the Company

Recent updates

First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

Sequana Medical Announces Data on Alfapump® Safety and Quality of Life to Be Presented At EASL Congress 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sequana Medical NV to Report First Half, 2024 Results on Sep 19, 2024

Sequana Medical NV to Report First Half, 2024 Results on Sep 12, 2024

Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure

No longer forecast to breakeven

New minor risk - Financial data availability

Sequana Medical NV has filed a Follow-on Equity Offering in the amount of €12 million.

Price target decreased by 26% to €7.63

Sequana Medical NV, Annual General Meeting, May 23, 2024

Forecast to breakeven in 2026

New minor risk - Market cap size

Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure

Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director

Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome

Forecast to breakeven in 2024

First half 2023 earnings released: €0.65 loss per share (vs €0.68 loss in 1H 2022)

New major risk - Financial position

Sequana Medical NV to Report Q2, 2023 Results on Sep 14, 2023

Sequana Medical NV Announces First Patient Enrolled in Mojave, a US Randomized Controlled Phase 1/2a Study of DSR 2.0 for Treatment of Compostive Heart Failure

Forecast to breakeven in 2024

Sequana Medical NV Announces Completion of 1,000th Alfapump Implant

Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director

Price target decreased by 22% to €12.50

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sequana Medical Announces Successful Completion of Pre-Clinical Studies with its Second-Generation DSR Product for Congestive Heart Failure

Price target increased to €16.00

Sequana Medical NV Announces Positive Top-Line Results from SAHARA Ph. 2a Study of DSR 1.0 in Diuretic-Resistant Heart Failure Patients with Persistent Congestion and First Patient Dosed Successfully with DSR 2.0 in YUKON

High number of new directors

Sequana Medical NV Announces Positive Top-Line Results from the North American Pivotal POSEIDON study of the alfapump

First half 2022 earnings released: €0.68 loss per share (vs €0.66 loss in 1H 2021)

Sequana Medical NV to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Sequana Medical NV Announces Board Changes

Price target increased to €13.75

Sequana Medical NV Appoints Doug Kohrs as an Independent Non-Executive Director of the Company

Sequana Medical Completes Enrollment in Phase 2a SAHARA I DSR, Reports Disease-Modifying Profile for Short Term DSR

Price target decreased to €11.75

High number of new and inexperienced directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Sequana Medical Announces the Completion of Alfapump Implantations in Poseidon, the North American Pivotal Alfapump Study

Sequana Medical NV Receives Certification Under Mdr, the New European Medical Device Regulation

Sequana Medical Announces Positive Interim Results of SAHARA DESERT

First half 2021 earnings released: €0.66 loss per share (vs €0.62 loss in 1H 2020)

Independent Non-Executive Director Jason Hannon has left the company

Sequana Medical’s Results from RED DESERT Alfapump DSR® Study Presented as One of the Highlights At Heart Failure 2021 Online Congress

Full year 2020 earnings released: €1.25 loss per share (vs €1.22 loss in FY 2019)

Sequana Medical Announces Positive Results From Second Interim Analysis of North American Pivotal alfapump® Study (POSEIDON)

Sequana Medical Announces First Patient Enrolled in SAHARA DESERT

Sequana Medical NV Announces Positive Top-Line Results from the Red Desert Study with Repeated Dose Alfapump DSR® (Direct Sodium Removal) Therapy in Diuretic-Resistant Heart Failure Patients

Health Check: How Prudently Does Sequana Medical (EBR:SEQUA) Use Debt?

Full year 2020 earnings released: €1.25 loss per share (vs €1.22 loss in FY 2019)

Sequana Medical NV, Annual General Meeting, May 27, 2021

Price target lowered to €13.00

Did Sequana Medical's (EBR:SEQUA) Share Price Deserve to Gain 51%?

New 90-day high: €7.96

Do Institutions Own Sequana Medical NV (EBR:SEQUA) Shares?

Sequana Medical Announces Positive Interim Data from North American Pivotal Alfapump® Study (Poseidon)

New 90-day high: €7.00

Sequana Medical NV Announces Scientific Advisors Appointments

Sequana Medical NV to Report Fiscal Year 2020 Results on Mar 17, 2021

First half earnings released

New 90-day low - €6.02

Analyse CEO-vergoeding

CEO

Tenure

Compensatie